Anti-Mouse Ly-6C (Clone HK1.4) – Purified in vivo GOLD™ Functional Grade
Anti-Mouse Ly-6C (Clone HK1.4) – Purified in vivo GOLD™ Functional Grade
Product No.: L136
Clone HK1.4 Target Ly-6C Formats AvailableView All Product Type Monoclonal Antibody Alternate Names Lymphocyte antigen 6 complex, locus C Isotype Rat IgG2c Applications CyTOF® , IHC FF , in vivo , IP , PhenoCycler® , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Rat IgG2c κ Recommended Dilution Buffer Immunogen L3 cloned CTL cells Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2737549 Additional Applications Reported In Literature ? CyTOF® Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Rat Anti-Mouse Ly-6C (Clone HK1.4) recognizes an epitope on Mouse Ly-6C. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype. Background Most hematopoietic cells express one or more members of Ly-6 family. The expression of Ly-6 varies with development stage and activation. Ly-6C is a 14-17 kD GPI-linked surface protein expressed on mouse monocyte/macrophage cells, endothelial cells, neutrophils, and some T cell subsets. Ly-6C is reported to be an indicator of memory CD8+ T cells. Antigen Distribution The antigen is found on some monocyte/macrophage populations, endothelial cells, thymocytes, NK-cells, T-cell subsets and 40% of bone marrow cells from all mouse strains tested. Clone HK1.4 does not block the binding of clone RB6-8C5
NCBI Gene Bank ID UniProt.org Research Area Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Common In Vivo Applications of Clone HK1.4 in MiceClone Identification and Phenotyping Cell Depletion and Functional Studies Advanced Imaging and Multiplexing In Vitro Functional Assays Summary Table: Key Applications of HK1.4 In Vivo
Important Notes
ConclusionClone HK1.4 is a cornerstone reagent for in vivo mouse studies requiring precise identification and characterization of Ly-6C-expressing cells, with applications spanning basic immunology, advanced tissue imaging, and functional immune assays. Its specificity and validation across multiple platforms make it a reliable choice for researchers investigating the role of Ly-6C+ cells in health and disease. The most commonly co-used antibodies or proteins with HK1.4 (anti-Ly6C) in the literature are markers that help delineate immune cell subsets, particularly for monocyte phenotyping and leukocyte subset analysis. Key co-used antibodies include:
Typical applications are flow cytometry panels where combinations such as Ly6C (HK1.4), CD11b, F4/80, and Ly6G are used to map myeloid cell populations in blood, spleen, or tissue. These combinations allow researchers to:
In summary, HK1.4 is most often paired with CD11b, F4/80, Ly6G, CD45, CD3, CD8, and CD4 for comprehensive immune cell profiling in mice. Clone HK1.4 is a widely used monoclonal antibody targeting mouse Ly-6C (Ly6C1), and its key findings in scientific literature center on its applications in immunology, particularly for identifying and characterizing immune cell subsets. Primary ApplicationsClone HK1.4 has been extensively utilized across multiple experimental techniques. The antibody is employed in flow cytometry, immunohistochemistry, and in vitro activation assays for studying immune cell populations. Its versatility extends to in vitro activation studies, where it serves as a valuable tool for investigating immune cell behavior and function. Specificity and CompatibilityA notable finding regarding clone HK1.4 is its compatibility with other commonly used antibodies. Specifically, HK1.4 does not block the binding of clone RB6-8C5, another widely used antibody in the field. This non-interference property makes it particularly useful for multi-marker flow cytometry experiments where researchers need to simultaneously detect multiple cell surface markers. Unlike the 1A8 clone, which shows interference with RB6-8C5, HK1.4 maintains compatibility, allowing researchers to use both antibodies in combination studies. Target MoleculeThe antibody specifically recognizes Ly-6C (Ly6C1), an important cell surface marker used to distinguish different subsets of immune cells, particularly monocytes and lymphocytes in mice. This specificity has made clone HK1.4 an essential reagent for immunological research requiring precise characterization of immune cell populations. Dosing regimens for clone HK1.4, an anti-mouse Ly-6C antibody, exhibit significant variability depending on the experimental context and mouse model being studied. While specific published dosing protocols for HK1.4 are limited in the available literature, the general principles governing in vivo antibody dosing in mouse models provide insight into how such regimens are determined and adjusted. General Dosing ConsiderationsClone HK1.4 is a rat monoclonal antibody that recognizes mouse Ly-6C, a surface marker expressed on various myeloid cell populations including monocytes, macrophages, and certain granulocyte subsets. The antibody is typically supplied at a concentration of 0.5 mg/ml and requires titration for optimal performance in each specific application. Factors Influencing Dosing VariationsThe variability in HK1.4 dosing regimens stems from several key factors that differ across mouse models. The specific experimental objective—whether for cell depletion, functional blockade, or phenotypic analysis—fundamentally determines the dosing approach. Different mouse strains may also require adjusted doses due to variations in body weight, immune cell populations, and antibody clearance rates. The disease model context significantly impacts dosing decisions. For example, tumor models, infection studies, and autoimmune disease models each present unique challenges in terms of target cell accessibility, disease kinetics, and the desired duration of antibody effect. Similar antibodies used for myeloid cell depletion, such as RB6-8C5 (anti-Gr-1, which recognizes both Ly6G and Ly6C), typically employ doses of 200-250 μg per mouse administered intraperitoneally every 2-3 days for sustained depletion. Comparative Dosing Across ApplicationsIn broader immunotherapy contexts, antibody dosing in mice follows established patterns that likely inform HK1.4 usage. Immune cell-depleting antibodies generally require 100-250 μg per mouse administered 2-3 times per week via intraperitoneal injection. For instance, CD4 and CD8 T cell depletion studies use 100 μg per dose every 4 days, while other protocols employ 200-250 μg doses. When considering myeloid-targeted therapies more broadly, higher doses may be employed. Studies using anti-CSF-1 antibodies for myeloid cell modulation have utilized initial doses of 1 mg per mouse, followed by maintenance doses of 0.5 mg, demonstrating that myeloid-targeted interventions sometimes require more substantial antibody quantities. Route and Timing AdjustmentsThe route of administration remains relatively consistent across most in vivo antibody studies, with intraperitoneal injection serving as the standard approach due to its ease of administration and reliable systemic distribution. However, the timing between doses varies considerably based on antibody clearance kinetics and the regeneration rate of target cell populations. For sustained effects, dosing intervals typically range from every 2-3 days to weekly administrations, with more frequent dosing required when complete and continuous target cell depletion is necessary. The specific model's disease progression timeline also dictates whether pretreatment doses are needed or whether therapy begins concurrent with disease induction. Model-Specific OptimizationUltimately, each research application requires empirical optimization of HK1.4 dosing. Researchers must consider the baseline expression levels of Ly-6C in their specific mouse strain, the kinetics of the biological process under investigation, and whether the goal is transient modulation or sustained depletion of target populations. Pilot studies with dose-response curves and time-course analyses are recommended to establish the optimal regimen for each unique experimental context. References & Citations1.) Havran, W. L. et al. (1988) J. Immunol. 140(4):1034 2.) Gubin, M. et al. (2018) Cell. 175(4):1014–1030.e19 Journal Link Technical ProtocolsCertificate of Analysis |
Related Products
Formats Available
Prod No. | Description |
---|---|
L126 | |
L261 | |
L262 | |
L263 | |
L127 | |
L501 | |
L136 | |
L405 | |
L400 |
